UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

SUBMIT
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

Finish!
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

CLSI - M39

Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data

active, Most Current
Organization: CLSI
Publication Date: 1 January 2022
Status: active
Page Count: 192
scope:

This guideline provides individuals involved with assessment of cumulative antimicrobial susceptibility test data with recommendations for the storage, analysis, and presentation of the data. The antimicrobial susceptibility test data from individual patient's isolates available for analysis are assumed to be final, accurate and in a usable format for health care providers. Recommendations cover the preparation of reports (eg, routine and enhanced antibiograms) to guide selection of empirical antimicrobial therapy. Reference to preparation of reports for other purposes is briefly discussed. This guideline is intended for use by individuals involved with:

• Analyzing and presenting cumulative antimicrobial susceptibility test data generated from testing microbial isolates from both humans and animals from single or multiple facilities (eg, clinical microbiologists, pharmacists, physicians, veterinarians, epidemiologists, infection prevention practitioners)

• Using antibiograms and other types of cumulative antimicrobial susceptibility test data to make clinical decisions, participate in antimicrobial stewardship programs, and/or participate in public health initiatives (eg, clinical microbiologists, infectious diseases specialists and other clinicians, infection prevention practitioners, pharmacists, epidemiologists, other health care personnel, and public health officials)

• Designing information systems for the storage and analysis of antimicrobial susceptibility test data (eg, LIS vendors, electronic health record [EHR] vendors, manufacturers of diagnostic products that include epidemiology analysis software, and manufacturers of epidemiology analysis or surveillance software)

This guideline does not include procedures for selecting isolates for antimicrobial susceptibility testing (AST), performing AST, interpreting AST results, nor confirming the accuracy of AST results.

Document History

M39
January 1, 2022
Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data
This guideline provides individuals involved with assessment of cumulative antimicrobial susceptibility test data with recommendations for the storage, analysis, and presentation of the data. The...
January 1, 2014
Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline
The recommendations set forth in this document are intended to be used by individuals involved in the following: Analyzing and presenting antimicrobial susceptibility test data (eg, clinical...
February 1, 2009
Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline
The recommendations set forth in this document are intended to be used by individuals involved in the following: analyzing and presenting antimicrobial susceptibility test data (eg, clinical...

References

Advertisement